M G Rumi

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. pmc Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
    Alessio Aghemo
    A M Migliavacca Center for Liver Disease First, Division of Gastroenterology, IRCCS Fondazione Ca Granda Hospital, University of Milan, Milan, Italy
    Hepat Mon 11:918-24. 2011
  2. doi request reprint Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C
    M Rumi
    Hepatology Unit, San Giuseppe Hospital, Universita degli Studi di Milano, Milan, Italy
    J Viral Hepat 19:37-41. 2012
  3. doi request reprint Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
  4. ncbi request reprint Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study
    Maria Grazia Rumi
    AM Et A Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 12:1033-40. 2007
  5. ncbi request reprint Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough
    M G Rumi
    Division of Hepatology, Antonio e Angela Maria Migliavacca Center for Liver Disease and Fondazione Italiana Ricerca Cancro, Liver Cancer Unit, Ospedale Maggiore IRCCS and University of Milan, Italy
    J Viral Hepat 9:71-4. 2002
  6. doi request reprint Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy
    M E Mancuso
    Department of Medicine and Medical Specialities, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 7:1997-2005. 2009
  7. doi request reprint Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin
    L Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Aliment Pharmacol Ther 35:1434-42. 2012
  8. pmc Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients
    M G Rumi
    AM and A Migliavacca Centre for the Study of Liver Disease and Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Gut 54:402-6. 2005
  9. ncbi request reprint Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism
    A Bersano
    Department of Neurological Sciences Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 7 IRCCS, Via F Sforza 35, Universita degli Studi di Milano, Milano, Italy
    Eur J Intern Med 19:370-1. 2008
  10. ncbi request reprint Hepatitis C in haemophilia: lights and shadows
    M G Rumi
    Department of Gastroenterology and Endocrinology, A Bianchi Bonomi Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, 20122 Milan, Italy
    Haemophilia 10:211-5. 2004

Collaborators

Detail Information

Publications15

  1. pmc Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
    Alessio Aghemo
    A M Migliavacca Center for Liver Disease First, Division of Gastroenterology, IRCCS Fondazione Ca Granda Hospital, University of Milan, Milan, Italy
    Hepat Mon 11:918-24. 2011
    ..Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment...
  2. doi request reprint Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C
    M Rumi
    Hepatology Unit, San Giuseppe Hospital, Universita degli Studi di Milano, Milan, Italy
    J Viral Hepat 19:37-41. 2012
    ..Retrospective cohort studies and randomized prospective head-to-head trials have attempted to resolve the considerable controversy over this issue and support evidence-based treatment decisions...
  3. doi request reprint Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens...
  4. ncbi request reprint Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study
    Maria Grazia Rumi
    AM Et A Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 12:1033-40. 2007
    ..The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators...
  5. ncbi request reprint Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough
    M G Rumi
    Division of Hepatology, Antonio e Angela Maria Migliavacca Center for Liver Disease and Fondazione Italiana Ricerca Cancro, Liver Cancer Unit, Ospedale Maggiore IRCCS and University of Milan, Italy
    J Viral Hepat 9:71-4. 2002
    ..Hence, extended surveillance of HCV carriers with consistently normal or minimally elevated ALT values is warranted as these patients are at risk of ALT flares and may develop progressive liver disease...
  6. doi request reprint Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy
    M E Mancuso
    Department of Medicine and Medical Specialities, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 7:1997-2005. 2009
    ..Nonetheless, in HCV-infected hemophiliacs, who are considered to constitute a difficult-to-treat population, current treatment strategies yielded rates of SVR similar to those obtained in non-hemophiliacs...
  7. doi request reprint Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin
    L Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Aliment Pharmacol Ther 35:1434-42. 2012
    ..Homozygosity for the PNPLA3 p.I148M polymorphism influences steatosis and fibrogenesis in chronic hepatitis C (CHC)...
  8. pmc Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients
    M G Rumi
    AM and A Migliavacca Centre for the Study of Liver Disease and Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Gut 54:402-6. 2005
    ..We previously described hepatitis reactivation in two carriers of the hepatitis C virus (HCV) genotype 2c...
  9. ncbi request reprint Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism
    A Bersano
    Department of Neurological Sciences Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 7 IRCCS, Via F Sforza 35, Universita degli Studi di Milano, Milano, Italy
    Eur J Intern Med 19:370-1. 2008
    ..IFN-based therapy has been associated with high rates (20%) of central nervous system side effects, but only a few case reports exist on extrapyramidal side effects...
  10. ncbi request reprint Hepatitis C in haemophilia: lights and shadows
    M G Rumi
    Department of Gastroenterology and Endocrinology, A Bianchi Bonomi Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, 20122 Milan, Italy
    Haemophilia 10:211-5. 2004
    ..The development of newer interferon-based therapies provides an opportunity for modifying the natural history of HCV infection in a substantial number of haemophilic patients...
  11. ncbi request reprint Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients
    E Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    Transfusion 44:790-4. 2004
    ..In a recent randomized controlled study, only a minority (15%) of adult hemophiliacs with chronic HCV achieved a sustained virologic response to treatment with interferon (IFN) and ribavirin given at standard doses...
  12. ncbi request reprint High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients
    F De Filippi
    Angela Maria e Antonio Migliavacca Center for Liver Disease, Department of Internal Medicine, IRCCS Maggiore Hospital, University of Milan, Italy
    Dig Liver Dis 33:477-9. 2001
    ..Low levels of hepatitis C virus-RNA found in hepatitis G virus carriers suggest an interaction between these two viruses in immunosuppressed patients...
  13. ncbi request reprint Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients
    L Ronzoni
    Department of Clinical Sciences and Community, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
    J Viral Hepat 21:416-23. 2014
    ..In vitro, erythroid cell proliferation and differentiation were inhibited by both pegIFN and RBV. Both pegIFN and RBV have an inhibitory effect on erythroid proliferation and differentiation...
  14. doi request reprint Primary prophylaxis of variceal bleeding in cirrhotic patients: a cohort study
    A Dell'Era
    Department of Medical Sciences, University of Milan, IRCCS Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena Foundation, Milan, Italy
    Dig Liver Dis 40:936-43. 2008
    ..However, it has been suggested that these patients may respond poorly to band ligation...
  15. pmc Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data
    C Camma
    Istituto Metodologie Diagnostiche Avanzate, Consiglio Nazionale delle Ricerche, and Cattedra e Unità Operativa di Gastroenterologia, University of Palermo, Palermo, Italy
    Gut 51:864-9. 2002
    ..Retreatment with a combination of alpha interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies...